NASDAQ:CADL Candel Therapeutics (CADL) Stock Price, News & Analysis $6.02 +0.18 (+3.08%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$6.03 +0.01 (+0.17%) As of 04:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Candel Therapeutics Stock (NASDAQ:CADL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Candel Therapeutics alerts:Sign Up Key Stats Today's Range$5.84▼$6.0450-Day Range$4.67▼$7.0252-Week Range$3.79▼$14.60Volume475,967 shsAverage Volume823,040 shsMarket Capitalization$301.62 millionP/E RatioN/ADividend YieldN/APrice Target$22.00Consensus RatingBuy Company Overview Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts. Read More Candel Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreCADL MarketRank™: Candel Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 537th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingCandel Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCandel Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Candel Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Candel Therapeutics are expected to grow in the coming year, from ($1.47) to ($1.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Candel Therapeutics is -4.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Candel Therapeutics is -4.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCandel Therapeutics has a P/B Ratio of 4.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Candel Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.87% of the float of Candel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCandel Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Candel Therapeutics has recently decreased by 0.30%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCandel Therapeutics does not currently pay a dividend.Dividend GrowthCandel Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted17.87% of the float of Candel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCandel Therapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Candel Therapeutics has recently decreased by 0.30%, indicating that investor sentiment is improving. News and Social Media2.4 / 5News Sentiment0.38 News SentimentCandel Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Candel Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 9 people have searched for CADL on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows3 people have added Candel Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Candel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,476.00 in company stock.Percentage Held by Insiders16.60% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.93% of the stock of Candel Therapeutics is held by institutions.Read more about Candel Therapeutics' insider trading history. Receive CADL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CADL Stock News HeadlinesCandel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of "Buy" from AnalystsAugust 10 at 3:47 AM | americanbankingnews.comWith 44% stake, Candel Therapeutics, Inc. (NASDAQ:CADL) seems to have captured institutional investors' interestAugust 8 at 4:41 AM | finance.yahoo.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative... | InvestorPlace (Ad)Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth ConferenceJuly 30, 2025 | globenewswire.comCandel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409July 24, 2025 | proactiveinvestors.comCandel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic CancerJuly 24, 2025 | globenewswire.comCandel Therapeutics, Inc. Gains Inclusion in Multiple Russell Value ...July 11, 2025 | nasdaq.comCandel Therapeutics expands Russell Index presence following 2025 reconstitutionJuly 9, 2025 | proactiveinvestors.comSee More Headlines CADL Stock Analysis - Frequently Asked Questions How have CADL shares performed this year? Candel Therapeutics' stock was trading at $8.68 at the beginning of the year. Since then, CADL shares have decreased by 30.6% and is now trading at $6.02. How were Candel Therapeutics' earnings last quarter? Candel Therapeutics, Inc. (NASDAQ:CADL) announced its earnings results on Tuesday, May, 13th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of ($0.24) by $0.37. When did Candel Therapeutics IPO? Candel Therapeutics (CADL) raised $72 million in an IPO on Tuesday, July 27th 2021. The company issued 9,000,000 shares at $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO. Who are Candel Therapeutics' major shareholders? Top institutional investors of Candel Therapeutics include Geode Capital Management LLC (1.80%), Halter Ferguson Financial Inc. (1.55%), Tanager Wealth Management LLP (0.39%) and Janney Montgomery Scott LLC (0.05%). Insiders that own company stock include Paul B Manning, Estuardo Aguilar-Cordova, Paul Peter Tak, Francesca Barone, Seshu Tyagarajan, William Garrett Nichols, Charles Schoch, Jason Amello and Joseph C Papa. View institutional ownership trends. How do I buy shares of Candel Therapeutics? Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Candel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Candel Therapeutics investors own include Advanced Micro Devices (AMD), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Alphabet (GOOG), Meta Platforms (META) and Visa (V). Company Calendar Last Earnings5/13/2025Today8/10/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CADL CIK1841387 Webwww.candeltx.com Phone617-916-5445FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Price Target for Candel Therapeutics$22.00 High Price Target$25.00 Low Price Target$15.00 Potential Upside/Downside+265.4%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$55.18 million Net MarginsN/A Pretax MarginN/A Return on Equity-136.74% Return on Assets-63.13% Debt Debt-to-Equity Ratio0.01 Current Ratio4.64 Quick Ratio4.64 Sales & Book Value Annual Sales$120 thousand Price / Sales2,513.35 Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book4.27Miscellaneous Outstanding Shares50,100,000Free Float41,786,000Market Cap$301.60 million OptionableOptionable Beta-0.88 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:CADL) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.